About the ERCUSYN Register

The Register

The European Registry on Cushing’s Syndrome (the acronym of which is ERCUSYN) is a project initially supported by the European Comission Public Health Programme, currently owned by the European Society of Endocrinology (ESE).

This registry aims to gather comprehensive data at the EU level regarding clinical features, diagnostic procedures, and therapeutic strategies for patients with Cushing’s Syndrome (CS).

Its journey began in 2006, when a group of leading European endocrinologists teamed up to apply for a Public Health Programme call, successfully securing initial funding for three years (2007–2010). Nearly two decades since its inception, the project remains highly active and has successfully compiled data from more than 3,030 patients as of May 2026.

Among the aims of the registry are to increase the awareness among general practitioners or primary care physicians throughout Europe, to make an earlier diagnosis and hopefully improve the long term prognosis and “normalize” the increased morbidity and mortality associated with this syndrome if not treated correctly, prevent the impairment in Quality of Life, and set up European guidelines for diagnosis and therapeutic strategy, etc.

From the beginning, it was clear that this should be a European initiative, and the European Society of Endocrinology has been a partner from the start, supporting the project in many ways.

The database has been sponsored by the EU, ESE, Novartis, Ipsen, HRA and ESTEVE. Currently ERCUSYN involves more than 65 centers from over 27 countries.